How to manage tremor and rigidity caused by antipsychotic medications, such as first-generation (FGA) or second-generation (SGA) antipsychotics like quetiapine (quetiapine) or olanzapine (olanzapine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 13, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Managing Antipsychotic-Induced Tremor and Rigidity

Quetiapine is the preferred antipsychotic when extrapyramidal symptoms (EPS) like tremor and rigidity are a concern, as it has a significantly lower risk of causing or worsening these symptoms compared to other antipsychotics. 1, 2

Differentiating Types of Antipsychotic-Induced Movement Disorders

Drug-Induced Parkinsonism (DIP)

  • Clinical presentation: Bradykinesia, rigidity, rhythmic tremor (typically bilateral)
  • Timing: Appears within hours to weeks of starting antipsychotic or increasing dose
  • Distribution: Symmetric, affecting limbs and trunk
  • Associated features: Masked facies, shuffling gait, postural instability

Tardive Dyskinesia (TD)

  • Clinical presentation: Involuntary, abnormal facial movements (lip smacking, puckering, chewing, tongue protrusion)
  • Timing: Delayed onset (typically after ≥3 months of treatment)
  • Distribution: Often affects orofacial region first, may progress to limbs and trunk
  • Course: May be permanent even after medication discontinuation

Risk Factors for Antipsychotic-Induced EPS

  • Medication-related:

    • First-generation antipsychotics (higher risk than second-generation)
    • High-potency agents (haloperidol, fluphenazine)
    • Higher doses
    • Rapid dose escalation
    • Polypharmacy with other D2 antagonists (e.g., metoclopramide) 3

  • Patient-related:

    • Elderly patients
    • Very young patients
    • Male gender
    • Previous history of EPS or tremors
    • Substance abuse
    • Dementia with Lewy bodies (extremely high risk) 4

Management Algorithm for Antipsychotic-Induced Tremor and Rigidity

Step 1: Assess and Confirm Diagnosis

  • Determine if symptoms are drug-induced parkinsonism vs. tardive dyskinesia
  • Rule out other causes (Parkinson's disease, Wilson's disease, etc.)
  • Evaluate medication history, timing of symptom onset, and pattern of symptoms

Step 2: Consider Medication Adjustment

  1. Switch to lower-risk antipsychotic:

    • Quetiapine has the lowest risk of EPS and is preferred for patients with existing movement disorders 1, 2
    • Consider low-dose clozapine for treatment-resistant cases with severe EPS

  2. Dose reduction:

    • If clinically feasible, reduce the dose of the current antipsychotic
    • Use the lowest effective dose to minimize EPS risk

Step 3: Pharmacological Management of EPS

  • For drug-induced parkinsonism:

    • First-line: Anticholinergic medications (benztropine 1-2 mg/day) 4
    • Alternative: Amantadine (preferred if patient has both DIP and TD) 5
    • Caution: Anticholinergics can worsen TD and should be avoided in elderly patients

  • For tardive dyskinesia:

    • Consider VMAT2 inhibitors (valbenazine, deutetrabenazine)
    • Avoid anticholinergics as they may worsen TD
    • Switching to quetiapine may reduce TD symptoms 1

Step 4: Monitoring and Follow-up

  • Regular assessment using standardized scales (AIMS, SAS)
  • Monitor for symptom improvement or worsening
  • Adjust treatment plan based on response

Special Considerations

Dementia with Lewy Bodies

  • Extreme sensitivity to antipsychotics with high risk of severe EPS and neuroleptic malignant syndrome
  • Avoid typical antipsychotics completely
  • If antipsychotic treatment is absolutely necessary, use quetiapine at low doses 4

Neuroleptic Malignant Syndrome

  • Rare but life-threatening complication
  • Presents with hyperthermia, rigidity, altered mental status, autonomic instability
  • Requires immediate discontinuation of antipsychotic and supportive care
  • Can occur with any antipsychotic, including atypicals like olanzapine 6

Practical Recommendations

  • When initiating antipsychotics, start with low doses and titrate slowly
  • Regularly monitor for early signs of EPS
  • Avoid combining multiple dopamine antagonists when possible
  • Consider prophylactic anticholinergics for high-risk patients receiving high-potency antipsychotics
  • For patients with history of EPS, prefer quetiapine or other low-EPS-risk antipsychotics
  • Remember that anticholinergics may help with DIP but can worsen TD 5

By following this structured approach, clinicians can effectively manage antipsychotic-induced tremor and rigidity while maintaining adequate control of psychiatric symptoms.

References

4
Guideline

Management of Dementia with Lewy Bodies

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Should benztropine (anticholinergic agent) be stopped before starting Austedo (deutetrabenazine) in a patient with tardive dyskinesia (TD)?
How should I manage a medication regimen including Abilify (Aripiprazole) 15mg daily, Buspar (Buspirone) 10mg, Cymbalta (Duloxetine) 60mg, Seroquel (Quetiapine) 200mg daily, and Vraylar (Cariprazine) 3mg daily for a patient with tardive dyskinesia, anxiety, and depression?
What are the alternatives to benztropine (anticholinergic agent) for treating parkinsonism?
What medication is a patient with involuntary, repetitive, non-rhythmic facial grimacing and chewing movements with occasional tongue protrusions most likely taking, given a history of psychiatric treatment with a medication for the past year?
What is the maximum dose of Ingrezza (valbenazine) that can be prescribed for a 69-year-old patient experiencing twitching and shaky movements while taking 80mg at bedtime?
What is the optimal management approach for a new amputee with heart failure?
How to manage a patient with anastomotic leakage after total gastrectomy and Oesophagojejunostomy (total removal of stomach and surgical connection between esophagus and jejunum) without signs of sepsis, confirmed by Gastrografin (contrast agent) study, on the 4th postoperative day?
At what level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation should I decrease the dose of rosuvastatin (Crestor)?
How to manage a patient with a confirmed anastomotic leak after total gastrectomy and esophagojejunostomy, with no signs of sepsis, on the 4th postoperative day?
What is the management for a bleeding patient with elevated fibrinogen levels?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question